On April 1, 2026, the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron), a once daily oral glucagon-like peptide 1 (GLP-1) receptor agonist developed by Eli Lilly and Company.
Foundayo is indicated for chronic weight management in adults with obesity, or overweight adults who have at least one weight-related comorbidity.
What sets Foundayo apart
Unlike other currently available injectable GLP-1 medications, Foundayo is administered orally once daily, offering a non-injectable alternative that may positively influence patient adherence and long-term utilization trends.
Once-daily Foundayo utilizes a stepwise dose escalation schedule designed to improve gastrointestinal tolerability and reduce unwanted side effects.
Foundayo works by activating the GLP 1 receptor, thereby regulating appetite, reducing caloric intake, and promoting weight loss. In clinical trials, treatment with Foundayo resulted in statistically significant and clinically meaningful reductions in body weight over 72 weeks (compared to placebo), with a greater average weight loss observed at higher doses.
Why this affects workers’ compensation and claims management
GLP‑1 receptor agonists continue to be associated with rapid growth in utilization and pharmacy spend. The availability of an oral option may further expand use by lowering administration barriers and increasing patient acceptance. For payers and claims professionals, this highlights considerations around formulary management, prior authorization requirements, duration of therapy, and long‑term cost management.
Potential impact on recovery
Weight reduction and improved metabolic health may support functional capacity, mobility, and overall recovery in injured workers — particularly in claims that include obesity‑related comorbidities. However, the chronic nature of therapy and associated costs warrant careful review to ensure alignment with medical necessity and recovery goals.
Safety considerations
Common adverse effects associated with Foundayo are primarily gastrointestinal, including nausea, diarrhea, constipation, and vomiting.
Additional risks include pancreatitis, gallbladder disease, acute kidney injury related to volume depletion, and hypoglycemia when used in combination with insulin or insulin secretagogues. Concomitant use with another GLP 1 receptor agonist is not recommended.
Foundayo includes an FDA boxed warning for the potential risk of thyroid C cell tumors; therefore, this medication is contraindicated in patients with a personal or family history of medullary thyroid carcinoma.
Bottom line
Foundayo introduces a new oral GLP‑1 option for chronic weight management. While its clinical benefits are consistent with other GLP‑1 products, its oral administration and anticipated utilization impact are important considerations for workers’ compensation stakeholders.